COMP <GO>
ANAB vs LLY // GROSS PROFIT MARGIN
AnaptysBio Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ANAB 4
— LLY 6
■ METRIC PARITY
LAST: $48.64 (-3.68%) • MKT CAP: $1.44B
gross-margins
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANAB VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANAB | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 32.36% | +52.64 | ANAB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.7x | 36.4x | -30.72 | ANAB | /valuation <GO> |
| Free Cash Flow Yield | 1.36% | 2.30% | -0.94 | LLY | /fcf-yield <GO> |
| Operating Margin | 75.00% | 40.21% | +34.79 | ANAB | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 31.90% | -37.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 157.00% | 45.51% | +111.49 | ANAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 66.6 | -19.86 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANAB REV | LLY REV | ANAB GROSS % | LLY GROSS % | ANAB FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $234.6M | $65.18B | — | 83.0% | $19.6M | $16.81B |
| FY 2024 | $91.3M | $45.04B | — | 81.3% | -$135.7M | $8.82B |
| FY 2023 | $17.2M | $34.12B | — | 79.3% | -$120.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANAB // BETA —
LLY // BETA 0.51